OMIC - Singular Genomics Systems Inc Debt to Book Capitalization Ratio

Corporate company logo of Singular Genomics (OMIC)

Singular Genomics Systems (OMIC) generates revenue from robotic DNA sequencing that eliminates manual labor. The company's debt relative to its balance sheet capitalization reflects the dynamics of its credit load, where the 0.44 level serves as a critical benchmark. Expenses are rising due to costly air freight for fragile instruments, while small-batch equipment production hinders the reduction of unit costs.

OMIC - Singular Genomics Systems Debts to Net Assets over the range 07/04/2022 - 03/01/2025
Finished products of Singular Genomics Corp

This indicator reflects the dependence of the balance sheet structure on debt capital relative to equity. A decrease in this metric suggests conservative management, although an excessive avoidance of leverage limits return on assets. Analyzing the ratio of borrowed funds to capitalization allows for an assessment of the issuer's financial stability. For Singular Genomics Systems (OMIC), this is critical due to a technological defeat in the sequencing race. The loss of market position makes the debt load burdensome while seeking new strategies.

Competitors of Singular Genomics Systems

Debts to Book Capitalization TEM (Tempus AI Inc)|qiagen.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio IONS (Ionis)|RGEN - Debts to Net Assets|Avidity - Debts to Book Capitalization|CRSP (CRISPR) - Debts to Net Assets|Debt to Book Capitalization Ratio GeneDx Holdings Corp. (WGS)|Debt to Book Value Ratio ultragenyx.com|BEAM: Debts to Book Capitalization|Debt to Net Assets Sarepta Therapeutics SRPT|Debt to Book Value TWST (Twist Bio)|10x - Debts to Book Capitalization|NTLA - Debt to Book Capitalization Ratio|STOK - Debt to Book Capitalization Ratio|BLFS: Debts to Book Capitalization|WVE (Wave Life Sciences Ltd) - Debts to Book Capitalization|MAZE - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio Sionna Corp (SION)|Prime Medicine, Inc. (PRME) - Debt to Book Value|Debt to Net Assets Ratio tayshagtx.com (TSHA)|QURE (uniQure) - Debts to Book Capitalization|Debt to Net Assets MeiraGTx Holdings MGTX|RGNX (Regenxbio) - Debts to Book Capitalization|SLDB: Debts to Book Value|Debt to Book Capitalization Ratio Ocugen, Inc.|PACB (pacb.com) - Debt to Book Value Ratio|Debt to Book Capitalization Ratio BNTC (Benitec Biopharma)|Debts to Book Value DSGN|Debt to Book Capitalization Ratio RCKT (Rocket Pharmaceuticals Inc)|Debt to Book Value 4D Molecular Corp (FDMT)|Debts to Book Capitalization LXEO|Debts to Net Assets Korro Bio Inc. KRRO|EDIT: Debts to Book Capitalization|SLN: Debt to Book Value|proqr.com - Debt to Book Capitalization Ratio|Debts to Net Assets Codexis|SGMO - Debt to Book Value|Debt to Net Assets Ratio NAUT|MGX (Metagenomi) - Debt to Book Capitalization Ratio|Debts to Net Assets Precision BioSciences Inc. DTIL|GBIO: Debt to Book Value|Boundless Bio Inc - Debts to Book Value|Debt to Book Capitalization Ratio XCUR (Exicure Corp)|Imunon, Inc. (IMNN) - Debts to Net Assets|PHIO - Debt to Book Value|Mustang Bio (MBIO) - Debt to Book Capital|Debts to Book Capitalization RNAZ (TransCode Therapeutics Inc.)|Debts to Book Value BNGO|Debt to Book Capitalization Ratio APDN (Applied DNA Sciences)|Debt to Book Value BLUE (bluebirdbio.com)|Debt to Book Capitalization Ratio IPA|Omega Therapeutics Inc - Debts to Net Assets|RGLS (Regulus Therapeutics Inc) - Debt to Book Capitalization Ratio|SYRS: Debts to Book Value|TBIO (Telesis Bio, Inc.) - Debt to Book Capitalization Ratio|traconpharma.com (TCON) - Debt to Book Value|UBX: Debts to Book Capitalization